{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ni J"],"funding":["Shanghai Action Plan for Science, Technology and Innovation","Shanghai Oriental Talent Program (Outstanding Project)","Noncommunicable Chronic Diseases-National Science and Technology Major Project","Shanghai Leading Talent Program of Eastern Talent Plan","Three-year Action Program of Shanghai Municipality for Strengthening the Construction of the Public Health System"],"pagination":["434-442"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12673452"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["<h4>Aims</h4>Serum 1,5-anhydroglucitol (1,5-AG) indicates glycemic control over 1-2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long-term outcomes in type 2 diabetes has not been fully established. Therefore, our study intends to examine the correlation between 1,5-AG and risk of all-cause and cardiovascular mortality.<h4>Methods</h4>In this real-world cohort study, 3721 patients with type 2 diabetes were classified by 1,5-AG levels (<6.0 and ≥6.0 μg/mL). Cox proportional hazards regression models served to analyse the link between 1,5-AG levels and risk of all-cause and cardiovascular mortality, while restricted cubic splines were employed to investigate linearity of this association.<h4>Results</h4>Across a median 7.4-year"],"journal":["Diabetes, obesity & metabolism"],"pubmed_title":["Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study."],"pmcid":["PMC12673452"],"funding_grant_id":["GWVI-11.2-YQ07","LJ2024121","GWVI-11.1-49","23JS1401000","2024ZD0532001","2024ZD0532000"],"pubmed_authors":["Ni J","Lu W","Wang C","Chen L","Lu J","Cai J","Wang Y","Su H","Xia T","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.","description":"<h4>Aims</h4>Serum 1,5-anhydroglucitol (1,5-AG) indicates glycemic control over 1-2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long-term outcomes in type 2 diabetes has not been fully established. Therefore, our study intends to examine the correlation between 1,5-AG and risk of all-cause and cardiovascular mortality.<h4>Methods</h4>In this real-world cohort study, 3721 patients with type 2 diabetes were classified by 1,5-AG levels (<6.0 and ≥6.0 μg/mL). Cox proportional hazards regression models served to analyse the link between 1,5-AG levels and risk of all-cause and cardiovascular mortality, while restricted cubic splines were employed to investigate linearity of this association.<h4>Results</h4>Across a median 7.4-year","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-07T04:43:44.071Z","creation":"2026-06-07T03:07:08.972Z"},"accession":"S-EPMC12673452","cross_references":{"pubmed":["41090407"],"doi":["10.1111/dom.70214"]}}